BSX’s Mahoney details outlook on up-and-coming businesses, including renal denervation and ICDs

Boston Scientific logo

Boston Scientific’s (NYSE:BSX) got a busy road ahead, with regulatory approvals and market launches in the works for products in some of its hottest business divisions.

During a conference held in Marlborough, Mass., today, incoming CEO Michael Mahoney – currently listed as president – detailed the outlook for 7 of the company’s up-and-coming divisions, including for the newly acquired Cameron Health subcutaneous ICD and the highly competitive renal denervation market.

Mahoney described the timeline as a "high-level strategy of gaining share in our core business, expanding globally, moving into some smart adjacencies that are growing quickly that leveraging our strength, and also cost productivity."

Alair asthma treatment – 20 countries and 200 sites by the end of the year
Boston Scientific’s Alair bronchial thermoplasty system, which provides relief for patients with persistent asthma, was the star of today’s presentation.

The Alair system already has CE Mark approval in the European Union and FDA approval for the U.S. (since March), and Mahoney predicted that the worldwide market for bronchial thermoplasty will hit $1 billion by 2020.

The Alair system delivers precise thermal energy to lung tissue via bronchoscope to reduce excessively smooth muscle, decreasing the airways’ ability to constrict.

The procedure won reimbursement from the Centers for Medicare & Medicaid Services at the start of this year.

Cameron S-ICD – FDA approval in 1st half of 2013
Boston Scientific on Friday closed its $1.35 billion buyout of Cameron Health, and with it the only subcutaneous implantable cardioverter eon the world market. Cameron’s S-ICD won CE Mark approval in the European Union in 2009, and Boston Scientific expects FDA approval and U.S. launch in 2013, Mahoney said today.

"We target this market at about $750 million for the subcutaneous ICD," Mahoney told attendees. "It truly is a very unique, novel device in healthcare. We’re very excited about exercising that option and closing that deal, and we anticipate FDA approval hopefully in the 1st half of 2013."

Clinical trial data debuted at the Heart Rhythm Society meeting in Boston last month found that the S-ICD system had comparable safety and effectiveness to traditional ICDs in treating life-threatening ventricular arrhythmias. The device is awaiting final word from the FDA, having won a positive vote from the federal watchdog agency’s advisory committee in April.

Renal denervation – 1st human use in Q3 2012
Boston Scientific is looking to stay apace with rivals in the highly competitive renal denervation market, which is currently led by pure-play device maker Medtronic (NYSE:MDT) and cross-town rival St. Jude Medical (NYSE:STJ).

BSX expects 1st human use in the 3rd quarter of 2012 for its RDN renal denervation system as treatment for resistant hypertension, predicting CE Mark approval and European commercialization in 2013. Mahoney pegged the renal denervation market at around $3 billion worldwide by 2020.

Medtronic’s Symplicity is already on the road to FDA review with clinical trials approved last summer in the U.S. St. Jude’s Enlightn, the 1st to use multiple electrodes, won CE Mark approval last month in the European Union.

Boston Scientific has "a number of organic programs currently taking place to enter the hypertension market," Mahoney says, and the company expects U.S. trials in 2014.

Transcatheter aortic valves – CE Mark in second half of 2013

Boston Scientific’s Lotus transcatheter aortic valve system
designed to minimize valve leakage post-implant, should win CE Mark approval in the European Union in the second half of 2013, at which point the company expects to launch a the device in Europe.

The company acquired the Lotus system in 2011 with the $450 million buyout of Sadra Medical, and Mahoney pegged the market at about $3 billion by 2020.

BSX implanted the 1st 11 patients with its Lotus TAVI system in Australia in the Reprise I trial, which was unveiled earlier this year, and the Reprise II trial, which will be used to support a bid for CE Mark approval, should close enrollment in the 1st half of 2013.

"We believe there are some unique feature benefits of this in terms of retrievability, and it also leverages our commercial sales force that we have around the world," Mahoney said.

The company is a few steps behind rivals Edwards Lifesciences (NYSE:EW) and Medtronic, which already have devices on the market.

Edwards’ Sapien landed FDA clearance in November 2011 for treatments of patients too sick to undergo open-heart surgery. Medtronic’s CoreValve TAVI system won CE Mark approval in the European Union in March 2007, and is expected to hit the U.S. market in 2014.

Synergy partially resorbable drug-eluting stents – CE Mark in late 2012
Boston Scientific’s next-generation Synergy drug eluting stents with a resorbable drug and polymer coating, may win CE Mark approval in the European Union as early as this year.

"This is a product that will have a 3 month drug-elution time, where after the 3 months both the drug and the polymer are gone which will leave the benefit of the long-sustaining bare-metal stent," Mahoney said. "We believe this platform combined with our Promus Element Plus platform will really position us, Boston Scientific, to have 2 leading platforms in the market to gain share in that business."

The company expects full European commercial launch in the second half of 2013, and will begin its Evolve II U.S. trials possibly as early as the 2nd half of this year. Market approval in the U.S. and Japan will likely come in 2016, according to BSX.

Mahoney pegged the global market at more than $4 billion by 2020.

Watchman left atrial appendage closure device – FDA approval and U.S. launch in 2013
Boston Scientific’s Watchman heart implant, designed to trap blood clots, is slated for FDA approval and U.S. launch in 2013.

The Watchman device may be an important tool for preventing stroke in high-risk atrial fibrillation patients, according to research unveiled at the Hearth Rhythm Society meeting in Boston last month.

The device already has CE Mark and is on the market in Europe.

"This is about a half-billion dollar market where Boston Scientific will be the leader in this business, leveraging our current channel with electrophysiologists," Mahoney said.

RSS From Medical Design & Outsourcing

  • Vicon captures a new development in motion capture (mocap)
    Vicon announced the launch of its new flagship camera platform, the Vicon Vantage. Drawing on over 30 years’ of motion capture (mocap) experience, the Vantage platform combines innovative technology with accessible design to open up motion capture to a broader audience. Vicon is a motion capture technology specialist company for science and life industries. Advances in […]
  • Satel’s latest product sets a new milestone in radio manufacturing
    The new Satelline TR4, from the Finnish manufacturer of radio data transmission systems, Satel sets a new milestone. The compact UHF transceiver with transmitting power of 1,000 mW is compatible with the protocols of Pacific Crest, Trimble and Satel. The type certifications in all important regions of the world make the TR4 ideal for integration […]
  • SCHURTER announces retirement of founder and management changes
    SCHURTER announced the retirement of founder Bruno H. Schurter on June 29, 2015. The company, founded in 1982 in Petaluma, California, will change management effective July 1, 2015. Bruno H. Schurter, president and CEO will retire after 33 years of heading up the privately held company, which is a subsidiary of SCHURTER Holding AG, founded in […]
  • Silicone: Expanding the horizon for modern medical devices
    Editor’s note: This article comes from Albright Technologies a manufacturer of custom silicone prototypes and provides volume production for medical, pharmaceutical, industrial, and other applications. Silicone materials have been around for more than 70 years. Beginning in the 1960s, silicones have played an important and evolving part in products designed for the medical field. Since that time, […]
  • DeNovo Sciences appoints a molecular diagnostics veteran as new CSO
    DeNovo Sciences, a producer of  liquid biopsy products, announced the appointment of Dr. Yixin Wang as Chief Scientific Officer (CSO). Dr. Wang is a veteran in molecular diagnostics where he has played significant R&D roles at large, multi-national companies including Parke-Davis/Pfizer, Veridex/Johnson & Johnson and Ventana/Roche. He will lead strategic initiatives for clinical development of DeNovo’s […]
  • Albright Technologies expands their silicone offerings
    Albright Technologies, a rapid silicone prototyper, has added silicone injection molding tooling and services to its product lineup. Liquid silicone injection molding became a suitable product offering as Albright expanded its offerings to better serve the silicone molding market. While silicone prototypes are commonly manufactured with low volumes in mind; injection molded liquid silicone rubber parts are […]
  • Applied Silver launches SilvaClean, silver treatment for textiles
    Applied Silver, Inc, is launching SilvaClean, a state-of-the-art silver treatment for textiles, at the Association for Professionals in Infection Control and Epidemiology’s (APIC) forty-second Annual Conference taking place at the Music City Center in Nashville, from June 27 through June 29. Hospitals have invested significantly in reducing the potential of infection through products and processes designed […]
  • Two-Component technology for improved quality of life
    In the field of injection molding and mold making, toolcraft covers all processes within the added value chain–from the design and selection of materials through to the creation of finished and qualified products. Complete solutions offered include injection molding for parts in the small and extremely small component areas, e.g. for medical technology. Utilizing two-component […]
  • GDS security protects medical devices from hackers
    As data breaches become more commonplace with serious consequences to personal, corporate and national security, it is clear that there is no shortage of accomplished and effective hackers ready to steal data and trade it on the open market. Global Data Sentinel (GDS) has the ability to provide retroactive security to remove access to email […]
  • BRAEBON and SomnoMed combine products to combat sleep apnea
    BRAEBON Medical Corporation announces that the DentiTrac oral appliance compliance system has passed a regulatory hurdle and is now FDA cleared in the USA for use with the SomnoDent oral device. BRAEBON congratulates SomnoMed for being the first company to achieve this milestone. “We are pleased DentiTrac is launching in the US market. Accurate oral appliance […]
  • For advanced shielded plastic connector solution, ODU delivers with latest product
    ODU, a company which designs and manufactures connector solutions and cable assemblies, is announcing ODU MEDI-SNAP EMC, the advanced shielded plastic connector solutions, to the US market. ODU MEDI-SNAP EMC is the latest addition to ODU’s Push-Pull circular connectors. The advanced medical connector solution is lightweight, autoclavable, sterilizable and it offers a touch proofed housing and reliable […]

Leave a Reply